Chapman University

Chapman University Digital Commons
Pharmacy Faculty Articles and Research

School of Pharmacy

1996

ls There Any Risk of a Withdrawal Syndrome
Associated with Abrupt Discontinuation of
Selective Serotonin Reuptake Inhibitors?
Rene A. Endow
University of Southern California

Mary Gutierrez
Chapman University, mgutierr@chapman.edu

Michael Z. Wincor
University of Southern California

Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles
Part of the Other Pharmacy and Pharmaceutical Sciences Commons
Recommended Citation
Endow RA, Gutierrez MA, Wincor MZ. Is there any risk of a withdrawal syndrome associated with abrupt discontinuation of selective
serotonin reuptake inhibitors? Calif Pharmacist. 1996;43:26-27.

This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.

ls There Any Risk of a Withdrawal Syndrome Associated with Abrupt
Discontinuation of Selective Serotonin Reuptake Inhibitors?
Comments

This article was originally published in California Pharmacist, volume 43, in 1996.
Copyright

California Pharmacists Association

This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/489

uu~est1on:

ls there any risk of a withdrawal
syndrome associated with abrupt discontinuation
of selective serotonin reuptake inhibitors?
BY RENE

A.

ENDOW, PHARM.D., MARY

A.

GUTIERREZ, PIIARM.D., AND NlrCIIAEL

hen the vast maj ori ty of depressed
patients were treated with tricyclic antidepressants, significant concern developed
among clinicians over potential withdrawal syndromes
when abruptly discontinuing pharmacotherapy. Other
than the possible recurrence of depressive symptoms,
the major fe ar was emergence of a transient, but nonetheless distressing, "cholinergie re bound." This was characterized by excessive salivation and lacrimation, urinary frequency, diarrhea and other gastrointestinal cornplaints, as weil as restlessness and sleep disturbances; it
was thought to be a result of abruptly discontinuing a
highly anticholinergic antidepressant that had be en used
at therapeutic doses for severa! months.
With the availability of the newer selective serotonin
reuptake inhibitors (SSRis), concern over a "cholinergie rebound" seemed unnecessary since these agents
demonstrate little or no anticholinergic activity. However, a review of the literature indicates that there may
be other withdrawal symptoms associated with
discontinuation of the SSRis. The time course and,
perhaps to a lesser extent, the frequency of these
symptoms appear to be correlated with the elimination
half-lives of the agents. For a summary of the differences
in half-lives, see Table 1.

Fluoxetine
Although fluoxetine has been available in the United
States longer than any of the other SSRis, reports of
withdrawal symptoms associated with its discontinuation have only recently appeared in the literature;
Berlin described three such cases. 3 In one case,
discontinuation of alpr.azola·m accompanied the
discontinuation of the patient's fluoxetine; therefore,
the results are difficult to interpret. However, in the
other two cases, only fluoxetine was involved. The more
striking case was that of a 36-year-old man who had
been treated with fluoxetine up to 40 mg per day. On
"Drug Information" is a regular feature edited by Jean
Noguchi, Pharm.D. California Pharmacist encourages readers to submit drug therapy questions to be answered. Contact
the managing editor at (916) 444-7811, x302, or write:
California Pharmacist, ATTN: Drug Information, 1112 I
Street, Suite 300, Sacramento, CA 95814.
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two separate occasions, his fluoxetine was abruptly
discontinued; both times, within two days, he experienced brief "bursts" of dizziness or vertigo lasting a few
seconds each and occurring numerous times each day.
With resumption of the fluoxetine, the dizziness ceased
within a few days.
The otherpatient, a34-year-oldman, even withgradual
tape ring of his 20 mg per day dosage of fluoxetine, experienced sensations of dizziness one week after stopping the
dn1g. Again, the sensations lasted a few seconds each and
occurred many times per day. Eight weeks after stopping
the drug, the sensations were fully gorre.

Sertraline
Two reports of withdrawal symptoms associated with
discontinuation of sertraline can be found in the literature.
A 46-year-old woman had her 100 mgper day of sertraline
abruptly discontinued. \Vithin two days, she reported
fatigue, gastrointestinal complaints, insomnia, impaired
memory, and flu-like symptoms. Addition of sertraline 25
mg daily resulted in rapid resolution of these complaints.
A more graduai tapering resulted in similar, but milder,
symptoms with each reduction in dosage. 4
A 22-year-old man was tapered over a period of 8
weeks from 150 mg per day of sertraline. One day after
his last dose of sertraline (50 mg), he complained of
"electric shocks" that were primarily in the neck and
chest and that progressed to his fingers and toes. They
each lasted about a second and occurred every five to 10
minutes. The sensations diminished over time and
completely stopped 13 weeks after discontinuation of
the sertraline. 5

Paroxetine
In 1993, the Committee on Safety of Medicines in
the United Kingdom noted that discontinuation of
paroxetine was associated with a mild and transient
withdrawal syndrome consisting of dizziness, sweating, nausea, insomnia, tremor and confusion. 6 Seven
reports can be found in the literature describing such
symptoms associated with paroxetine discontinuation.
The total of 17 patients includes both males and
females with an age range of 26 to 64 and typical daily
doses of 20 to 40 mg. s,ï- 12
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In general, the symptoms began within two to three
days of discontinuation, whether abrupt or, at times,
even following a taper and usually resolved over a period
of one to two weeks. In addition, sorne patients complained of "electrical shocks" which would start in the
upper body and move quickly down to the arms and
hands; these would last only a few seconds but could
occur constantly with motion. Interestingly, this cornplaint appeared to resolve more slowly than the other
withdrawal symptoms.

case reports; under such circumstances, we never quite
know what the denominator of the proportion is. It is
clear, however, in a number of cases that restarting the
withdrawn agent resulted in an immediate and complete resolution of the withdrawal symptoms. IfEllison's 16
estimate of a 5 percent incidence of the withdrawal
syndrome is correct, it would be wise to slowly and
carefully taper all patients (other than tho se in who rn
the potential risk of a slow taper outweighs the benefits)
who have been treated with any of the SSRis at a
therapeutic dose for an extended period of time.

Fluvoxamine
About the authors
There are three reports, involving a total of 17
patients, in which discontinuation of fluvoxamine has
been associated with withdrawal symptoms. 13-15 The
patients included both males and females with an age
range of 25 to 56 and daily doses of 100 to 300 mg. The
most frequent symptoms were dizziness/incoordination, headaches, nausea and irritability; in addition,
confusion, memory problems, low energy, and weakness have been reported. These symptoms generally
appear within one to two da ys of discontinuation, peak
within five days, and dissipate within approximately
two weeks.

At the time this article was written, Rene A. Endow,
Pharm.D., was a resident in psychiatrie pharmacy practice at the University of Southern ealifornia (USe)
School of Pharmacy.
Mary A. Gutierrez, Pharm.D., is an assistant professor
of clinical pharmacy at the use School of Pharmacy.
Michael Z. vVincor, Pharm.D., is an assistant professor of clinical pharmacy, psychiatry and the behavioral
sciences at the USe School of Pharmacy and School of
Medicine.
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Conclusion
There does appear to be sorne risk of a withdrawal
syndrome following abrupt discontinuation of SSRis; in
fact, even tapering may be associated with such a risk,
although perhaps a lesser one. The time course of this
phenomenon appears to be somewhat correlated with
the elimination half-life of the specifie agent. However,
other factors (e.g., binding affinities, variable effects on
serotonin receptor sensitivity) may make any such
predictions difficult. With respect to fluoxetine, the
occurrence of a withdrawal syndrome may be rare due
to the very protracted elimination of the drug and its
active metabolite from the body; on the other hand, the
phenomenon may not be noticed because the onset is so
long after discontinuation of the drug.
The exact incidence is difficult to determine since
most of the currently available information consists of

1. DeVane CL. "Pharmacokinetics of the newer antidepressants:
Clinical relevance." Am J Med, 1994; 97(suppl):6S-13S.
2. Grimsley SR, J ann M\V. "Paroxetine, sertraline and fluvoxamine:
New selective serotonin reuptake inhibitors." Clin Pharm, 1992;
11:930-57.
3. Berlin CS. "Fluoxetine withdrawal symptoms (letter)." J Clin
Psychiatry, 1996; 57:93-4.
4. Louie AK, Lannon RA, Ajari LJ. "Withdrawal reaction after
sertraline discontinuation (letter)."AmJ Psychiatry, 1994; 151:450-1.
S. Frost L, Lai S. "Shock-like sensations after discontinuation of
selective serotonin reuptake inhibitors (letter)." Am J Psychiatry,
1995; 152:810.
6. Gelenberg AJ, ed. "Postmarketing watch: Paroxetine in the
UK." Biol Ther Psychiatry, 1993; 16:25-8.
7. Barr LC, Goodman WK, Priee LH. "Physical symptoms associated with paroxetine discontinuation (letter)." Am J Psychiatry,
1994; 151:289.
8. Keuthen NJ, Cyr P, Bicciardi JA, Minichiello \VE, et al. "Medication withdrawal symptoms in obsessive-compulsive disorder pa-

Fluoxetine:

, : :1:-6,:'g~ys' ,
: , 4~ 16 :a:~ys :+< :

AUTUMN

1996

27

~· Tbankyoü, corporate members! ·
~bbot~ L~bRr~tori~~.s· • Abordi8. Lloyd •ln§urance :services
. ~ A~P:HARMA-L),S:.pl""làrmace.Ùtic~J Oivision ~Amgen •
....· . :· . ..... As,tra W$A1 :ln~. • .:Bal.lsÇt) :and ·Lomb Ph.arma9eutical •
· ; : · . · ..: · .: : ....: ,; :~~yèrCorpo(àtlqn~~~rg:en·Bru~~vv,ig Qqrporation •Bindley
. .: ~e·s!~r~.I~r:~:g:Cof1JpÇt0Y,• ç:a;r~lri"al Hea.ltb~ IJl.c? ~ Gioa~:en~va f?har:niaceutic~lsi
:. -,:.~li :Lill~; 9ci~ ;~0tl1pany;! Eo:r~?f Laboratbries; Jo~.: • :G18.~0 Wellcome lnc. •··
. ·: qf;l~~s:er:~9~f;maÇ.~~ti~$;; 1nè~ :Joho~cin::& ~p~~son :l':McKess?n Drùg Co~ pany
: ! M~l9n :PharrT~aceutical:s,:~ lnc: :•: NGV() Nor<;:lisk: PF!à~mac;~uticàls· 1ne • ·Park~-;
: p;a:vts~ ~i:vi w~~M~r:~~~~ert~!; 8~96E? ~~optatori.es··.:·$~Q~9i Pha~rnàceÜtic.aJs
QoJ~c;>r;~!i?~:·:Sc~erit:~!d h:a,.b():r~tbrie:s~~:·c~»e. I;J~iO:~ri C){jmp~ny :•tJr\it~d Pbarma~
tists Netvvprl{, h1c,: ~ Zen:eç:a: Pharmacèaticals· · · : · · · ; .: · ·
····
· ....

?!

!"lr~~mi~~~~1~~~1ili~!~!4Q~ho.~t~ni
:. =.; ;.;, :.

ù "

~

•.•••.•..·... ....•.•,

:= . : .

l'iirJ:!eHQ~8JG~~~.è r $~6i:at; .~ Nn)~~~.:.;t\~t~a ,Me re~:. Jà~s~e~

::~kh~~14f~q~~t~~n~~~t~#~iî~t~;~~~~~;J~~~~~E
:.·~···;tr:c:~:tJ:lif~i~~:ty~t:o"riR:•:~.Ç)c~~-:p:?lbSi)·ra~O~i~~~S:c:b:E?;d~~.;~àl:}drà~~.riês':wyeth~·;,

~· i1~~r,~z~f:~P!~·~t?fi~?~i:f~rf9Pfr ~P~t·~~p~:u~iB't1~:;· ri··~···!~.~::.·~ f. :•.; •.r~ :.: ::·:·:.~···

tients treated with paroxetine (letter)." J Clin
Psychopharmacol, 1994; 14:206-7.
9. Phillips SD. "A possible paroxetine withdrawal syndrome (letter)." Am J Psychiatry,
1995; 152:645-6.
10. Pyke RE. "Paroxetine withdrawal syndrome (letter)." Am J Psychiatry, 1995;
152:149-50 .
11. Dominguez RA, Goodnick PJ. "Adverse
events after abrupt discontinuation of paroxetine."
Pharmacotherapy, 1995; 15:778-80.
12. Debattista C, Schatzberg AF. "Physical
symptoms associated with paroxetine withdrawal
(letter)." Am J Psychiatry, 1995; 152:1235-6.
13. Szabadi E. "Fluvoxamine withdrawal
syndrome (letter)." Br J Psychiatry, 1992;
160:283-4.
14. Mallya G, \Vhite K, Gunderson C. "Is
there a serotonergic withdrawal syndrome (letter)?" Biol Psychiatry, 1993; 33:851-2.
15. Black DW, Wesner R, Gabel J. "The
abrupt discontinuation of fluvoxamine in patients with panic disorder." J Clin Psychiatry,
1993; 54:146-9.
16. Ellison JM. "SSRI withdrawal buzz (letter)." J Clin Psychiatry, 1994; 55:544-5 . •!•

Outdated Software?
Pacifie Pharmacy Computers offers the following:
• A Total Pharmacy Management System

• Com piete D rug Utilization Review
• TAR Form Generator (lntegrated with the System)
• T AR Trac king
• Cycle Fill for Board & Ca re and N ursing Home Patients
• Auto Filling Ability
• Handles Rapid Remit Transmissions
• Service 24 hours/day and 7 dayslweek

PPil-800-231-4772
28

C.ALIFORNIA PHARNIACIST

